Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries? Alan Haycox Editorial 07 June 2018 Pages: 731 - 732
Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails? Fernando AntoñanzasRoberto Rodríguez-IbeasCarmelo A. Juárez-Castelló Leading Article 15 February 2018 Pages: 733 - 743
Discounting in Economic Evaluations Arthur E. AttemaWerner B. F. BrouwerKarl Claxton Review Article Open access 19 May 2018 Pages: 745 - 758
Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Matt StevensonAbdullah PandorRuth Wong Review Article 03 March 2018 Pages: 759 - 768
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Shijie RenIñigo BermejoMatt Stevenson Review Article Open access 03 March 2018 Pages: 769 - 778
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review Alex DiamantopoulosEmily WrightToby M. Maher Systematic Review Open access 01 March 2018 Pages: 779 - 807
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin Guy NeffWoodie Zachry III Systematic Review Open access 12 April 2018 Pages: 809 - 822
The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests Alison F. SmithMike MessengerClaire Hulme Systematic Review Open access 03 March 2018 Pages: 823 - 835
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England Irina A. TikhonovaNicola HuxleyMartin Hoyle Original Research Article 01 March 2018 Pages: 837 - 851
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist Przemysław HolkoPaweł KawalecAndrzej Pilc Original Research Article Open access 17 April 2018 Pages: 853 - 865
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK Vanessa BuchananWill SullivanBruce Kirkham Original Research Article Open access 25 May 2018 Pages: 867 - 878
Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis” Ena Singh Letter to the Editor 04 May 2018 Pages: 879 - 879
Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin Guy NeffWoodie Zachry III Correction Open access 01 June 2018 Pages: 881 - 881
